Novartis' application for voluntary retirement is closed

Recruitment of applicants for 2 weeks

Organization reorganization together

There are still concerns about waiting and retirement

The application for ERP, which is underway by Novartis Korea, has ended.

 

Attention is focusing on whether the relatively quiet voluntary retirement will be completed without any problems.

 

According to the pharmaceutical industry on the 8th, the application for voluntary retirement, which was conducted by Novartis Korea for about two weeks, has recently been closed.

 

The company announced the implementation of voluntary retirement on the 25th of last month.

 

Novartis Korea is in the process of integrating and dividing its business units at the same time.

 

The plan is to combine the Rx division and the anti-cancer drug division to unite innovative drugs into one and form a new division that collects patented drugs.

 

New drugs such as Kymriah and Zolgensma are bound to be innovative drugs, and old drugs such as relatively low-cost chronic disease drugs are expected to be classified as patent expired drugs.

 

ERP was also carried out in the process of integrating and dividing business units.

 

The compensation condition is '2n+8' and additional compensation is given for each year.

 

This means that an average salary of eight months is paid twice the number of years of service, and an additional six months' worth of employees for 10 to 15 years of service and 12 months' worth of employees for more than 15 years.

 

It is reported that voluntary retirement is taking place in a relatively quiet atmosphere.

 

It went through a meeting with the labor union before the announcement of his voluntary retirement, and it was found that it was not a coercive atmosphere because it did not specify the target.

 

However, the key is how the company will respond if the applicant falls short of the desired retirement size the company thinks.

 

The higher the number of years of service, the higher the desired retirement compensation.

 

Last year, there was also a backlash against proceeding with voluntary retirement despite no management difficulties due to high profits.

 

The NPU, which includes Novartis Korea, said at a meeting of National Assembly aides on the 7th, "Novartis is the world's most profitable pharmaceutical company last year, and this restructuring is also due to the unification of its business unit, not management reasons." The NPU said, "Novatis Korea also announced its voluntary retirement with a very passive attitude that it has no management difficulties, but has no choice but to follow global decisions." In the process, there is a concern about the risk of forced voluntary retirement, such as encouraging retirement, the NPU said.

 

The union said, "There were some applicants for voluntary retirement, and the exact number of people is being determined.

 

However, it remains to be seen how much the company thinks of voluntary retirement and whether it will make artificial adjustments beyond the legal part if they do not reach that level, he said.

 

In response, the union said, "We have completed the application for voluntary retirement smoothly, and all procedures are conducted transparently and fairly in accordance with the law.

 

The union said, "We will respect the will of our employees as much as possible and will not exercise compulsory pressure such as urging them to retire."